Rigel Pharmaceuticals RIGL REZLIDHIA — Payment of cost share to collaboration partner
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:PaymentOfCostShareToCollaborationPartner.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's rezlidhia — payment of cost share to collaboration partner.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner?
- Rigel Pharmaceuticals (RIGL) reported REZLIDHIA — payment of cost share to collaboration partner of $1.33M in Q4 2026.
- How has Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner changed year-over-year?
- Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner decreased by 0.0% year-over-year, from $1.33M to $1.33M.
- What does REZLIDHIA — payment of cost share to collaboration partner mean?
- This metric tracks the cash outflows related to the reimbursement or sharing of development, commercialization, or operational expenses with a collaboration partner for REZLIDHIA. It quantifies the company's commitment to shared cost structures defined in joint venture or licensing contracts. Analyzing these payments helps investors assess the efficiency of the partnership and the impact of shared expenses on product-level profitability.